Increases In Reimbursement For Brand-Name Drugs in Part D

The report was released on June 4, 2018, by the Office of the Inspector General (OIG) for the federal Department of Health and Human Services (HHS). The OIG analyzed prescription drug event records from 2011 through 2015 for reimbursement amounts and utilization changes for brand name drugs covered by Medicare Part D. The OIG also analyzed the number of prescriptions and average unit costs for brand name drugs that were reimbursed by Part D in every year from 2011 to 2015. Further, the OIG evaluated beneficiary out-of-pocket costs for brand name drugs in Part D from 2011 to . . .